Andrew Cooper
Stock Analyst at Raymond James
(3.22)
# 1,077
Out of 4,749 analysts
127
Total ratings
49.11%
Success rate
0.88%
Average return
Main Sectors:
Stocks Rated by Andrew Cooper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TMO Thermo Fisher Scientific | Reiterates: Outperform | $650 → $667 | $593.75 | +12.34% | 6 | Feb 3, 2025 | |
| RVTY Revvity | Reiterates: Outperform | $140 → $145 | $123.69 | +17.23% | 7 | Feb 3, 2025 | |
| DHR Danaher | Downgrades: Market Perform | n/a | $214.26 | - | 8 | Feb 3, 2025 | |
| AVTR Avantor | Maintains: Outperform | $29 → $26 | $21.87 | +18.88% | 13 | Jan 21, 2025 | |
| HAE Haemonetics | Upgrades: Strong Buy | $120 | $66.15 | +81.41% | 7 | Nov 8, 2024 | |
| HOLX Hologic | Maintains: Outperform | $93 → $95 | $71.72 | +32.46% | 10 | Nov 5, 2024 | |
| EXAS Exact Sciences | Reiterates: Market Perform | n/a | $55.24 | - | 8 | Sep 26, 2024 | |
| CDNA CareDx | Downgrades: Market Perform | n/a | $23.32 | - | 16 | May 13, 2024 | |
| NTRA Natera | Downgrades: Outperform | $68 → $85 | $176.56 | -51.86% | 5 | Feb 20, 2024 | |
| QDEL QuidelOrtho | Downgrades: Outperform | $100 → $76 | $42.53 | +78.70% | 12 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $27 | $47.57 | -43.24% | 2 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $5.39 | - | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $52.09 | - | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $13.88 | - | 14 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $27 | $12.77 | +111.43% | 3 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $45.06 | - | 8 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $16.33 | +175.57% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.91 | - | 5 | Sep 22, 2021 |
Thermo Fisher Scientific
Feb 3, 2025
Reiterates: Outperform
Price Target: $650 → $667
Current: $593.75
Upside: +12.34%
Revvity
Feb 3, 2025
Reiterates: Outperform
Price Target: $140 → $145
Current: $123.69
Upside: +17.23%
Danaher
Feb 3, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $214.26
Upside: -
Avantor
Jan 21, 2025
Maintains: Outperform
Price Target: $29 → $26
Current: $21.87
Upside: +18.88%
Haemonetics
Nov 8, 2024
Upgrades: Strong Buy
Price Target: $120
Current: $66.15
Upside: +81.41%
Hologic
Nov 5, 2024
Maintains: Outperform
Price Target: $93 → $95
Current: $71.72
Upside: +32.46%
Exact Sciences
Sep 26, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $55.24
Upside: -
CareDx
May 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $23.32
Upside: -
Natera
Feb 20, 2024
Downgrades: Outperform
Price Target: $68 → $85
Current: $176.56
Upside: -51.86%
QuidelOrtho
Feb 14, 2024
Downgrades: Outperform
Price Target: $100 → $76
Current: $42.53
Upside: +78.70%
Nov 13, 2023
Upgrades: Outperform
Price Target: $27
Current: $47.57
Upside: -43.24%
Jul 19, 2023
Initiates: Market Perform
Price Target: n/a
Current: $5.39
Upside: -
Jul 19, 2023
Initiates: Market Perform
Price Target: n/a
Current: $52.09
Upside: -
May 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $13.88
Upside: -
Mar 3, 2023
Maintains: Outperform
Price Target: $25 → $27
Current: $12.77
Upside: +111.43%
Jan 18, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $45.06
Upside: -
Nov 18, 2022
Initiates: Outperform
Price Target: $45
Current: $16.33
Upside: +175.57%
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $3.91
Upside: -